title: [Pharmacoeconomics of therapy in invasive candidiasis].
abstract: BACKGROUND
  Invasive candidiasis episodes have increased during last years and they have been related with high rates of crude mortality. Invasive candidiasis-related deaths have not diminished significantly with the introduction of antifungals in the past decade. Finantial managers are worried about extra costs from acquisition of new antifungal agents.
  
  
  OBJECTIVE
  This review includes the main studies age-stratified to assess different variables related to the economic burden of invasive candidiasis.
  
  
  METHODS
  Systematic review of biomedic databases including Medline, PubMed and EMBASE.
  
  
  RESULTS
  The studies show hospital stay as the main variable related with higher impact in the increase of invasive candidiasis costs. Acquisition costs of antifungals have a very low impact in the invasive candidiasis costs.
  
  
  CONCLUSIONS
  Pharmacoeconomics applied in candidiasis invasive therapy must avoid assessing acquisition costs of antifungals exclusively, needing to include both direct and indirect costs associated with this fungal infection. The cost of antifungal acquisition represents a low impact in the overall economic burden of this fungal infection. Further pharmacoeconomics evaluations should be performed including similar definitions to decrease the possible bias in results interpretation.
authors.affiliation: Servicio de Farmacia, Hospital del Mar, Barcelona, España. sgrau@imas.imim.es
authors.forename: Santiago
authors.initials: S
authors.lastname: Grau-Cerrato
authors.forename: Olivia
authors.initials: O
authors.lastname: Ferrández-Quirante
mesh_terms: D000328:Adult; D000367:Age Factors; D000935:Antifungal Agents / Q000191:economics* / Q000627:therapeutic use; D002177:Candidiasis / Q000188:drug therapy* / Q000191:economics; D002648:Child; D003428:Cross Infection / Q000188:drug therapy / Q000191:economics; D016527:Drug Costs; D005380:Financing, Government / Q000706:statistics & numerical data; D005382:Financing, Personal / Q000706:statistics & numerical data; D016469:Fungemia / Q000188:drug therapy* / Q000191:economics; D017721:Hospital Costs; D006760:Hospitalization / Q000191:economics; D006801:Humans; D007230:Infant, Low Birth Weight; D007231:Infant, Newborn; D007234:Infant, Premature; D007235:Infant, Premature, Diseases / Q000188:drug therapy / Q000191:economics; D007902:Length of Stay / Q000191:economics; D011446:Prospective Studies; D016459:Prosthesis-Related Infections / Q000188:drug therapy / Q000191:economics; D012189:Retrospective Studies
chemical_list: D000935:Antifungal Agents